Pulsenmore

Company Overview

Snapshot

Founded in October 2014, Pulsenmore is led by founder Elazar Sonnenschein and operates with 51–200 employees. The company has raised a total of $119.57 million across 8 funding rounds from 6 investors. In August 2026, Pulsenmore received a grant from the Israel Innovation Authority for an AI development project.

Business overview

Pulsenmore develops universally accessible home ultrasound devices for remote care, enabling patients to self-scan by connecting their smartphones to a handheld ultrasound cradle. These scans are then automatically sent for remote clinical assessment by healthcare providers. The company's technology primarily focuses on at-home prenatal ultrasound for remote assessment of fetal well-being, empowering women to proactively manage pregnancies. Pulsenmore operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare, serving markets in Israel, the United States, and Europe.

Strategic signal

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound, pioneering a new era of prenatal care in the U.S. This authorization is a significant validation of the company's technology and opens up a substantial new market, signaling strong growth potential and regulatory acceptance for its innovative remote healthcare solutions.

Company Intelligence Q&A

What was a significant recent regulatory achievement for Pulsenmore?

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound device, which is expected to expand access to prenatal care in the U.S.

What was a key strategic partnership announced by Pulsenmore in 2026?

In June 2026, Pulsenmore announced a strategic partnership with Ouma Health to expand access to remote prenatal care across the United States.

What recent grant did Pulsenmore receive for AI development?

In July 2026, Pulsenmore was selected for an Israel Innovation Authority and Ministry of Health program to lead a $1 million AI development project.

When did Pulsenmore commence trading on Nasdaq?

Pulsenmore commenced trading on Nasdaq in January 2026, following its FDA authorization and plans to expand its home prenatal ultrasound devices in the U.S.

What was a recent commercial engagement for Pulsenmore in the U.S.?

In February 2026, Pulsenmore announced its first commercial engagement with a leading U.S.-based medical center, building momentum after its FDA clearance.